Abstract
The Prostate Cancer Prevention Trial is a randomized double blind chemoprevention trial of 18,882 men. It is designed to test the difference in the histologically proven prostate cancer prevalence between a group of participants given finasteride and another given placebo for 7 years. We present an overview of the study design, details of the administrative structure of the study and a description of the successful implementation of the accrual phase.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Chemoprevention
-
Cholestenone 5 alpha-Reductase / antagonists & inhibitors
-
Enzyme Inhibitors / pharmacology*
-
Finasteride / pharmacology*
-
Humans
-
Male
-
Middle Aged
-
Prevalence
-
Prostatic Neoplasms / enzymology
-
Prostatic Neoplasms / epidemiology
-
Prostatic Neoplasms / prevention & control*
-
Randomized Controlled Trials as Topic / methods*
-
Randomized Controlled Trials as Topic / statistics & numerical data
-
Research Design
Substances
-
Enzyme Inhibitors
-
Finasteride
-
Cholestenone 5 alpha-Reductase